2023
The impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM).
Adelson K, Canavan M, Sheth K, Scott J, Westvold S. The impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: e18923-e18923. DOI: 10.1200/jco.2023.41.16_suppl.e18923.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useSystemic therapyCT patientsCare useImpact of receiptMean episode costReceipt of chemotherapyReceipt of immunotherapyICU useED costsIO patientsPharmacy costsOncology practiceEpisode costsTreatment decisionsDownstream careCare modelAmbulatory settingPart BPatientsImmunotherapy
2020
The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2020, 38: 2-2. DOI: 10.1200/jco.2020.38.29_suppl.2.Peer-Reviewed Original ResearchOncology Care ModelDrug costsCancer CenterLung cancerEpisode costsMean MedicareYale Cancer CenterClinical trial participationSystemic cancer therapyPart D drug costsCancer therapyLower drug costsCommon cancer typesChi-square testPayment modelsClinical factorsNovel cancer therapiesTrial participationOvarian cancerPatient episodesNovel therapiesCare modelCTR groupPharmaceutical costsAlternative payment modelsThe impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM). Journal Of Clinical Oncology 2020, 38: e19367-e19367. DOI: 10.1200/jco.2020.38.15_suppl.e19367.Peer-Reviewed Original ResearchOncology Care ModelDrug costsMean MedicareYale Cancer CenterMean drug costClinical trial participationSystemic cancer therapyLower drug costsCommon cancer typesChi-square testValue-based payment modelsPayment modelsClinical factorsCancer CenterTrial participationLung cancerEpisode costsCare modelCTR groupAlternative payment modelsCancer typesMean differenceCancer therapyCareEpisodes
2019
Effects of rising drug costs on efforts to control overall cost at a large academic cancer center.
Adelson K, Canavan M, Supalla S, Sedghi T, Chaudhry B, Sinanis N, Gross C. Effects of rising drug costs on efforts to control overall cost at a large academic cancer center. Journal Of Clinical Oncology 2019, 37: 2-2. DOI: 10.1200/jco.2019.37.27_suppl.2.Peer-Reviewed Original ResearchOncology Care ModelLarge academic cancer centerAcute care useAcademic cancer centerPost-acute careMean costCancer CenterCare useDrug costsEmergency department useCost of hospitalizationMean total costValue-based payment programsCost of pharmaceuticalsCancer HospitalCancer careDepartment useTotal episodesInpatient careMedicare claimsCare modelCareEpisodesUtilization categoriesPharmaceutical spendingUnderstanding cancer care coordination: Opening the black box.
Canavan M, Sedghi T, Gross C, Lane S, Bogdan J, Adelson K. Understanding cancer care coordination: Opening the black box. Journal Of Clinical Oncology 2019, 37: e18310-e18310. DOI: 10.1200/jco.2019.37.15_suppl.e18310.Peer-Reviewed Original ResearchIndirect patient careCare coordinatorsPatient careAcute care utilizationCare management programSite of careDirect patient careOncology Care ModelElderly patientsMultidisciplinary careTreatment complicationsCare utilizationCancer careSymptom assessmentCare coordinationOutpatient careCare modelCare plansHigh riskAcademic centersNurses' experiencesCancer supportPatientsCareActivity time